These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 7924868)
1. [A clinical study on the tumor associated antigen CA50 in the monitoring of genitourinary malignancies]. Li CL; Xu BZ; Chen ZZ Zhonghua Zhong Liu Za Zhi; 1994 Mar; 16(2):148-51. PubMed ID: 7924868 [TBL] [Abstract][Full Text] [Related]
2. [Clinical value of carbohydrate antigen 50 and carbohydrate antigen 242 in the diagnosis of colorectal carcinoma]. Huang CW; Bai L Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1116-8. PubMed ID: 12480590 [TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. Lucarotti ME; Habib NA; Kelly SB; Rothnie ND; Nelson O; Lindholm L; Cooper MJ; Wood CB; Williamson RC Eur J Surg Oncol; 1991 Feb; 17(1):51-3. PubMed ID: 1995358 [TBL] [Abstract][Full Text] [Related]
4. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer]. Huang C; Bei L; Liu T Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693 [TBL] [Abstract][Full Text] [Related]
5. The use of CA-50 radioimmunoassay test in diagnosis of urologic malignancy. Tie for second place Jobst award. Hershman MJ; Habib NA; Ferro MA; Williamson RC; Wood CB Am Surg; 1987 Dec; 53(12):691-4. PubMed ID: 3480697 [TBL] [Abstract][Full Text] [Related]
6. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. Zhu Y; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ J Urol; 2008 Nov; 180(5):2019-23. PubMed ID: 18801542 [TBL] [Abstract][Full Text] [Related]
7. [The detection of laryngeal carcinoma-associated antigens in tissue and serum using three mixed monoclonal antibodies against laryngeal cancer]. Chen O; Guan G; Jin C Zhonghua Er Bi Yan Hou Ke Za Zhi; 1996; 31(1):43-6. PubMed ID: 9275404 [TBL] [Abstract][Full Text] [Related]
8. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract]. Takami H; Furuuchi T; Ogata Y; Abe O Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. Bonner RB; Liebert M; Hurst RE; Grossman HB; Bane BL; Hemstreet GP Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):971-8. PubMed ID: 8959319 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798 [TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of serum SCC Ag in patients with squamous cell carcinoma of the lung]. Zeng L Zhonghua Wai Ke Za Zhi; 1993 Mar; 31(3):143-5. PubMed ID: 8223022 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary. Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350 [TBL] [Abstract][Full Text] [Related]
14. Sialyl Lewis-Xi antigen in patients with gynecologic tumors. Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045 [TBL] [Abstract][Full Text] [Related]
15. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. Shvarts O; Seligson D; Lam J; Shi T; Horvath S; Figlin R; Belldegrun A; Pantuck AJ J Urol; 2005 Mar; 173(3):725-8. PubMed ID: 15711252 [TBL] [Abstract][Full Text] [Related]
16. [Advances regarding tumor markers in bladder cancer]. Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884 [TBL] [Abstract][Full Text] [Related]
17. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433 [TBL] [Abstract][Full Text] [Related]
18. Clinical value of serum squamous cell carcinoma antigen in the management of sinonasal inverted papilloma. Yasumatsu R; Nakashima T; Masuda M; Kuratomi Y; Shiratsuchi H; Hirakawa N; Tomita K; Yamamoto T; Komune S Head Neck; 2005 Jan; 27(1):44-8. PubMed ID: 15459916 [TBL] [Abstract][Full Text] [Related]
19. The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence. Blumenstein BA; Ellis WJ; Ishak LM J Urol; 1999 Jan; 161(1):57-60; discussion 60-1. PubMed ID: 10037368 [TBL] [Abstract][Full Text] [Related]
20. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer]. Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]